{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:06:29Z","timestamp":1772165189570,"version":"3.50.1"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Joint Funds of the Research and Development Program of Science and Technology of Henan Province of China","award":["232301420091"],"award-info":[{"award-number":["232301420091"]}]},{"name":"Henan Medical Science and Technology Research and Development Program Project","award":["LHGJ20230682"],"award-info":[{"award-number":["LHGJ20230682"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic management of idiopathic pulmonary fibrosis (IPF) remains challenging. IPF patients frequently exhibit a hypercoagulable state, and anticoagulant therapy has emerged as a potential strategy; however, its clinical utility remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To systematically evaluate the efficacy and safety of anticoagulant therapy in IPF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of randomised controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>Comprehensive searches were conducted in PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, Wanfang Data, VIP, and CBM databases for randomised controlled trials (RCTs) investigating anticoagulant therapy in IPF, from database inception to February 2025. Two investigators independently screened the literature, extracted data, and assessed risk of bias. Meta-analysis was performed using RevMan 5.3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seven RCTs involving 504 patients with IPF were included. Compared with control groups not receiving anticoagulants, anticoagulant therapy significantly improved PaO\n                      <jats:sub>2<\/jats:sub>\n                      (MD\u2009=\u200911.64, 95% CI 7.09\u201316.18,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), SaO\n                      <jats:sub>2<\/jats:sub>\n                      (MD\u2009=\u20094.44, 95% CI 2.42\u20136.47,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and HGF levels (MD\u2009=\u2009108.74, 95% CI 88.58 to 128.90,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) but significantly reduced the mMRC score (MD\u2009=\u2009\u22120.38, 95% CI \u22120.62 to \u22120.14,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002) and D-dimer levels (MD\u2009=\u2009-0.08, 95% CI \u22120.11 to \u22120.05,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). No significant difference was observed in PaCO\n                      <jats:sub>2<\/jats:sub>\n                      levels (MD\u2009=\u2009\u22124.26, 95% CI \u22129.09 to 0.56,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.08). Anticoagulant therapy did not demonstrate benefit in reducing all-cause mortality (RR\u2009=\u20093.46, 95% CI 1.57\u20137.61,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002) or adverse reactions (MD\u2009=\u20091.44, 95% CI 1.15\u20131.81,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Anticoagulant therapy may offer clinical benefits in IPF management. However, its lack of mortality benefit and safety concerns warrant cautious interpretation. Clinicians should carefully assess individual bleeding risks before initiating treatment. Due to the limited number of included studies and data constraints, further large-scale, high-quality, multicenter, and long-term RCTs are needed. Future research should prioritise risk stratification, optimised anticoagulation protocols and identification of biomarkers predictive of bleeding risk to inform clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>The study protocol was registered with PROSPERO (Registration number: CRD42022349940).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666251393078","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:34:04Z","timestamp":1762774444000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy and safety of anticoagulants in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3520-5466","authenticated-orcid":false,"given":"Jiamin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"},{"name":"The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province &amp; Education Ministry of P.R. China, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengzhou, People\u2019s Republic of China"},{"name":"Henan Key Laboratory of Chinese Medicine for Respiratory Diseases, Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7375-5220","authenticated-orcid":false,"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"},{"name":"The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province &amp; Education Ministry of P.R. China, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengzhou, People\u2019s Republic of China"},{"name":"Henan Key Laboratory of Chinese Medicine for Respiratory Diseases, Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0022-584X","authenticated-orcid":false,"given":"Guixiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"},{"name":"The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province &amp; Education Ministry of P.R. China, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengzhou, People\u2019s Republic of China"},{"name":"Henan Key Laboratory of Chinese Medicine for Respiratory Diseases, Henan University of Chinese Medicine, Zhengzhou, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3808-6586","authenticated-orcid":false,"given":"Hailong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450003, People\u2019s Republic of China"},{"name":"The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450003, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province &amp; Education Ministry of P.R. China, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengzhou 450046, People\u2019s Republic of China"},{"name":"Henan Key Laboratory of Chinese Medicine for Respiratory Diseases, Henan University of Chinese Medicine, Zhengzhou 450046, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1002"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00170-2018"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159709"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-73"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91744-6"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203740"},{"key":"e_1_3_4_10_2","first-page":"591","article-title":"Terapeutica anticoagulante na fibrose pulmonar idiopatica [Anticoagulant therapy for idiopathic pulmonary fibrosis]","volume":"11","author":"Kubo H.","year":"2005","unstructured":"Kubo H. Terapeutica anticoagulante na fibrose pulmonar idiopatica [Anticoagulant therapy for idiopathic pulmonary fibrosis]. Rev Port Pneumol 2005; 11: 591\u2013592.","journal-title":"Rev Port Pneumol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40248-016-0074-z"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2017.10.004"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2746"},{"key":"e_1_3_4_14_2","first-page":"1676","article-title":"Research progress of hypercoagulable state and anticoagulation therapy in idiopathic pulmonary fibrosis","volume":"41","author":"Lina Z","year":"2021","unstructured":"Lina Z, Lixia D. Research progress of hypercoagulable state and anticoagulation therapy in idiopathic pulmonary fibrosis. Int Respir J 2021; 41: 1676\u20131680.","journal-title":"Int Respir J"},{"key":"e_1_3_4_15_2","first-page":"74","article-title":"Research progress of anticoagulant therapy in idiopathic pulmonary fibrosis","volume":"36","author":"Li X","year":"2016","unstructured":"Li X, Liangan H. Research progress of anticoagulant therapy in idiopathic pulmonary fibrosis. Int Respir J 2016; 36: 74\u201378.","journal-title":"Int Respir J"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.10.019"},{"key":"e_1_3_4_17_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"e_1_3_4_21_2","first-page":"387","article-title":"Guidelines for diagnosis and treatment of idiopathic pulmonary (interstitial) fibrosis (Draft)","volume":"25","author":"Chinese Society of Respiratory Diseases","year":"2002","unstructured":"Chinese Society of Respiratory Diseases. Guidelines for diagnosis and treatment of idiopathic pulmonary (interstitial) fibrosis (Draft). Chin J Tuberc Respir Dis 2002; 25:387\u2013389.","journal-title":"Chin J Tuberc Respir Dis"},{"key":"e_1_3_4_22_2","first-page":"427","article-title":"Chinese expert consensus on diagnosis and treatment of idiopathic pulmonary fibrosis","volume":"39","author":"Interstitial lung disease group of Chinese Society of Respiratory Diseases","year":"2016","unstructured":"Interstitial lung disease group of Chinese Society of Respiratory Diseases. Chinese expert consensus on diagnosis and treatment of idiopathic pulmonary fibrosis. Chin J Tuberc Respir Dis 2016; 39: 427\u2013432.","journal-title":"Chin J Tuberc Respir Dis"},{"key":"e_1_3_4_23_2","first-page":"156","volume-title":"Systematic Review Guidance Manual","author":"Kehu Y.","year":"2010","unstructured":"Kehu Y. Systematic Review Guidance Manual. Beijing: People\u2019s Health Publishing House, 2010; 156-158."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_4_25_2","volume-title":"The effect of low molecular weight heparin sodium on the expression of serum HGF in patients with IPF and its clinical efficacy","author":"Yujie P.","year":"2009","unstructured":"Yujie P. The effect of low molecular weight heparin sodium on the expression of serum HGF in patients with IPF and its clinical efficacy Shanxi Medical University, 2009."},{"key":"e_1_3_4_26_2","first-page":"1833","article-title":"Observation of prothrombotic state and anticoagulation efficacy in patients with IPF","volume":"16","author":"Wenling L","year":"2011","unstructured":"Wenling L, Ruiqin W, Feng Y, et al. Observation of prothrombotic state and anticoagulation efficacy in patients with IPF. J Clin Pulmonol 2011; 16: 1833\u20131834.","journal-title":"J Clin Pulmonol"},{"key":"e_1_3_4_27_2","first-page":"99","article-title":"Clinical efficacy of low molecular weight heparin sodium in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Wang Shunying","year":"2012","unstructured":"Wang Shunying. Clinical efficacy of low molecular weight heparin sodium in patients with idiopathic pulmonary fibrosis. China Med Herald 2012; 9: 99\u2013100.","journal-title":"China Med Herald"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0314OC"},{"key":"e_1_3_4_29_2","first-page":"3599","article-title":"Observation on the effect of N-acetylcysteine combined with inhalation of low molecular weight heparin on idiopathic pulmonary fibrosis","volume":"37","author":"Zheng Land Xian En F","year":"2016","unstructured":"Zheng Land Xian En F. Observation on the effect of N-acetylcysteine combined with inhalation of low molecular weight heparin on idiopathic pulmonary fibrosis. Guangdong Medicine 2016; 37: 3599\u20133601.","journal-title":"Guangdong Medicine"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1818OC"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0006PP"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13242099"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2009.0780"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12091"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12631"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2023.11.003"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2014.04.008"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.10.023"},{"key":"e_1_3_4_40_2","first-page":"507151","article-title":"Anti-inflammatory effects of heparin and its derivatives: a systematic review","volume":"2015","author":"Mousavi S","year":"2015","unstructured":"Mousavi S, Moradi M, Khorshidahmad T, et al. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci 2015; 2015: 507151.","journal-title":"Adv Pharmacol Sci"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.05.009"},{"key":"e_1_3_4_42_2","first-page":"1569","article-title":"Research progress on the correlation between hepatocyte growth factor and the development of pulmonary fibrosis","volume":"27","author":"Li QY","year":"2022","unstructured":"Li QY, Feng T, Zheng PC, et al. Research progress on the correlation between hepatocyte growth factor and the development of pulmonary fibrosis. J Clin Pulmon Med 2022; 27: 1569\u20131573.","journal-title":"J Clin Pulmon Med"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.778972"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114537"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2296"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.03.016"},{"key":"e_1_3_4_47_2","first-page":"242","article-title":"A comparative study of the efficacy of second-line platinum-based combination regimen and single-agent regimen in elderly patients with advanced non-small cell lung cancer","volume":"39","author":"Xiangtao Y","year":"2019","unstructured":"Xiangtao Y, Huijuan W, Peng L, et al. A comparative study of the efficacy of second-line platinum-based combination regimen and single-agent regimen in elderly patients with advanced non-small cell lung cancer. Chin J Gerontol 2019; 39: 242\u2013245.","journal-title":"Chin J Gerontol"},{"key":"e_1_3_4_48_2","article-title":"Analysis of the application status of outcome indicators in randomised controlled trials of idiopathic pulmonary fibrosis","volume":"62","author":"Jiaqi D","year":"2021","unstructured":"Jiaqi D, Xuanlin L, Jiamin C, et al. Analysis of the application status of outcome indicators in randomised controlled trials of idiopathic pulmonary fibrosis. J Tradit Chin Med 2021; 62: 1040\u20131045+1058.","journal-title":"J Tradit Chin Med"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251393078","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666251393078","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251393078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:34:19Z","timestamp":1763170459000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666251393078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["10.1177\/17534666251393078"],"URL":"https:\/\/doi.org\/10.1177\/17534666251393078","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666251393078\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251393078\/v2\/review2","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"17534666251393078"}}